Pharmaceuticals
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 26.
Q1Medicare.com Brings 2010 Medicare Prescription Drug Plan Information Online
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Q1Medicare.com (http://www.q1medicare.com) now has the newly released 2010 Medicare Part D prescription drug plan information online. Summaries of the 2010 prescription drug plan landscapes are provided both on a national and state level. An overview of important Part D plan changes is also provided in a textual format for each state. For more details, Medicare beneficiaries can use the online PDP-Finder tool to review information on all available 2010 Part D plans across the country, including monthly plan premiums, cost-sharing amounts for different formulary tiers, and whether the plan qualifies for the Low-Income Subsi...
Source: PRWeb: Medical Pharmaceuticals - October 30, 2009 Category: Pharmaceuticals Source Type: news
BIKAM and Dalton Medicinal Chemistry Expand and Renew Research AgreementEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BIKAM, pioneers in the discovery and development of potential therapeutic agents for the treatment of degenerative eye diseases and ocular disorders and Dalton Medicinal Chemistry have jointly announced a renewal of their exclusive worldwide collaboration and agreement to discover and develop new ophthalmology therapeutics. (PRWeb Oct 29, 2009)
Read the full story at http://www.prweb.com/releases/Dalton_BIKAM/Medicinal_Chemistry/prweb3131644.htm
Source: PRWeb: Medical Pharmaceuticals - October 30, 2009 Category: Pharmaceuticals Source Type: news
New MyKidz Comfort Patch™ Soothes Little Stuffy Noses this Cold and Flu SeasonEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Comfort Patch™ is a new, safe, non-drug option that soothes kids' noses and throats with vapors that work up to 8 hours. (PRWeb Oct 29, 2009)
Read the full story at http://www.prweb.com/releases/Drug-Free/Cold_Flu_Medicine/prweb3134334.htm
Source: PRWeb: Medical Pharmaceuticals - October 30, 2009 Category: Pharmaceuticals Source Type: news
Spectrum Pharmacy Products Announces a Proactive Approach to the Prevention of Melamine ContaminationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Spectrum Pharmacy Products announced that they are fully committed to ensuring that every one of their products that contains, or is produced, using one of the pharmaceutical components identified by the U.S. FDA Center for Veterinary Medicine (CVM), a part of FDA's Center for Drug Evaluation and Research (CDER), is free from melamine contamination. Spectrum has developed a proactive approach to the prevention of melamine contamination by documenting the source of all raw materials utilized in the manufacturing process, the assessment of the manufacturing process itself, and the evaluation of other potential sources o...
Source: PRWeb: Medical Pharmaceuticals - October 30, 2009 Category: Pharmaceuticals Source Type: news
InVitria Reports Successful Cell Culture Performance of Zap-CHO, a Defined and Cost Effective CHO Cell Culture Media SupplementEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
New Chinese hamster ovary ("CHO") cell culture media supplement delivers enhanced speed, growth and productivity while replacing undefined media components such as hydrolysates or fetal bovine serum ("FBS") in CHO cell culture. (PRWeb Oct 28, 2009)
Read the full story at http://www.prweb.com/releases/2009/10/prweb3120484.htm
Source: PRWeb: Medical Pharmaceuticals - October 30, 2009 Category: Pharmaceuticals Source Type: news
Smith & Nephew Plc: Total Voting RightsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
London, UK (MARKET WIRE)
Source: Market Wire - Pharmaceuticals and Biotech - October 30, 2009 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Medical and Healthcare SNN Source Type: news
Local Houses of Worship Unite in Support of Organ and Tissue DonationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
HARRISBURG, Pa., Oct. 30, 2009 (GLOBE NEWSWIRE) -- Members of faith-based communities across the state will recognize the most precious gift of life-saving efforts -- through organ and tissue donations during National Donor Sabbath weekend. This three-day inclusive observance, which occurs annually during the second weekend of November, is a special time for religious leaders to educate their congregations about the importance of organ and tissue donation and the critical need for more donors.
Source: Medical News (via PRIMEZONE) - October 30, 2009 Category: Pharmaceuticals Source Type: news
Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of NeurologyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Preliminary Results Indicate that Florbetaben PET Imaging
Scans May Differentiate Patients with Probable Alzheimer's Disease
from Healthy Volunteers
BANGKOK, Oct. 30 /PRNewswire/ -- Bayer HealthCare presented
results from a global Phase II study of...
Source: Drugs.com - Clinical Trials - October 30, 2009 Category: Pharmaceuticals Source Type: clinical trials
Magic’s Howard seek 30K for Florida HospitalEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Orlando Magic center Dwight Howard is giving $30,000 to Florida Hospital for Children through his Big Change for Kids help fund.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 30, 2009 Category: Pharmaceuticals Source Type: journals
Doctor sentenced for HIV infusion fraudEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A Miami doctor was sentenced to six-and-a-half years in prison and ordered to pay more than $3.4 million in restitution for his role in a Medicare and Medicaid HIV-infusion fraud.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 30, 2009 Category: Pharmaceuticals Source Type: journals
What You Can Do to Help Your Uninsured PatientsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Here's how to make your care more accessible to patients who might otherwise miss getting the services they need. Family Practice Management
Source: Medscape Business of Medicine Headlines - October 30, 2009 Category: Pharmaceuticals Tags: Family Medicine/Primary Care Source Type: info
PerkinElmer rises on positive outlookEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
PerkinElmer shares jumped in early trading Friday after the release of third quarter earnings that, despite a sharp drop in year-over-year profits, showed an improving outlook for the biotechnology and health-care technology company. (PKI)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 30, 2009 Category: Pharmaceuticals Source Type: journals
Idenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis C Virus (HCV)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CAMBRIDGE, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Idenix
Pharmaceuticals, Inc. (NASDAQ:IDIX) , a biopharmaceutical company
engaged in the discovery and development of drugs for the treatment
of human viral diseases, today announced presentations...
Source: Drugs.com - Clinical Trials - October 30, 2009 Category: Pharmaceuticals Source Type: clinical trials
TomoTherapy to cut 10% of work forceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
TomoTherapy Inc., the Madison producer of targeted radiation cancer treatment systems, said it is cutting 10 percent of its work force in response to soft economic and market conditions. (TOMO)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 30, 2009 Category: Pharmaceuticals Source Type: journals
Presentations of Cempra Pharmaceutical's CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA CandidateEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Presentations Highlight: - Potency against Contemporary S.
aureus strains, Including MRSA - Low Level Resistance Development
despite Decades of Use Outside the U.S. - PK-PD Underlying Novel
Oral Loading Dose Regimen to minimize future...
Source: Drugs.com - Clinical Trials - October 30, 2009 Category: Pharmaceuticals Source Type: clinical trials
Data Presented on Cempra Pharmaceutical's CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae IsolatesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Complete coverage against S. pneumoniae strains
from three continents - Highly active against multidrug-resistant
strains; more potent than telithromycin, linezolid and
vancomycin
CHAPEL HILL, N.C., Oct. 29 /PRNewswire/ --...
Source: Drugs.com - Clinical Trials - October 30, 2009 Category: Pharmaceuticals Source Type: clinical trials
Hospitals, Healthcare Providers to Save with New Premier Agreements for Vascular Compression Therapy ProductsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CHARLOTTE, N.C., Oct 30--(HSMN NewsFeed)--Premier Purchasing Partners, LP, today announced new agreements for vascular compression therapy products have been awarded to Compression Therapy Concepts of Eatontown, N.J., a women-owned business, and Tyco Healt... Devices, Group PurchasingPremier Purchasing, Compression Therapy Concepts, Tyco Healthcare
Source: HSMN NewsFeed - October 30, 2009 Category: Pharmaceuticals Source Type: news
Stryker Announces Change in Chairman of the Board of DirectorsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
KALAMAZOO, Mich., Oct. 30 / (HSMN NewsFeed) -- Stryker Corporation (NYSE: SYK ) announced today that after a highly successful and distinguished 32-year career with Stryker Corporation, John W. Brown, has announced his decision to retire as Chairman of th... Devices, PersonnelStryker
Source: HSMN NewsFeed - October 30, 2009 Category: Pharmaceuticals Source Type: news
Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of PortugalEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Cancer Patients to Benefit from State-of-the-Art RapidArc and Novalis Tx Installations
PORTO, Portugal, Oct. 30 (HSMN NewsFeed) -- Cancer patients in northern Portugal will gain access to advanced cancer treatments with the acquisition of seven new tr... Devices, OncologyVarian Medical Systems, Novalis Tx, radiosurgery, RapidArc, radiotherapy
Source: HSMN NewsFeed - October 30, 2009 Category: Pharmaceuticals Source Type: news
Sanofi-aventis Delivers a Solid Performance in Third Quarter 2009Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
2009 Q3 Change Change at 2009 Change Change at
on a constant 9 months on a constant
reported exchange reported exchange
...
Source: Drugs.com - Pharma News - October 30, 2009 Category: Pharmaceuticals Source Type: news
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall SurvivalEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Eisai Plans to Submit Marketing Authorization Applications for Eribulin Mesylate in Locally Advanced or Metastatic Breast Cancer
WOODCLIFF LAKE, N.J., Oct. 30 (HSMN NewsFeed) -- Eisai Inc. today announced preliminary results from a recently completed ... Biopharmacetuicals, OnocologyEisai, eribulin mesylate, breast cancer
Source: HSMN NewsFeed - October 30, 2009 Category: Pharmaceuticals Source Type: news
Watson Names R. Todd Joyce Senior Vice President and Chief Financial Officer; Succeeds Mark W. DurandEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MORRISTOWN, N.J., Oct. 30 (HSMN NewsFeed) -- Watson Pharmaceuticals (NYSE: WPI ) today announced that R. Todd Joyce has been named Senior Vice President and Chief Financial Officer (CFO) effective immediately. Mr. Joyce succeeds Mark W. Durand, who has d... Biopharmaceuticals, PersonnelWatson Pharmaceuticals
Source: HSMN NewsFeed - October 30, 2009 Category: Pharmaceuticals Source Type: news
YM Biosciences Reports Additional Results From Nimotuzumab Phase III Study In Children With Glioma Presented By Oncoscience AgEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MISSISSAUGA, ON, Oct. 29 /PRNewswire-FirstCall/ -- YM
BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product
development company that identifies and advances a diverse
portfolio of promising cancer-related products at various stages...
Source: Drugs.com - Clinical Trials - October 30, 2009 Category: Pharmaceuticals Source Type: clinical trials
Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated CatheterEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
ST. LOUIS, Oct. 30 (HSMN NewsFeed) -- Stereotaxis received notice that the Celsius® RMT ThermoCool® catheter has received CE Mark for distribution in the European market. The product is the fifth advanced ablation catheter resulting from the on-g... Devices, RegulatoryStereotaxis, Biosense Webster, Celsius RMT ThermoCool, Niobe Magnetic Navigation
Source: HSMN NewsFeed - October 30, 2009 Category: Pharmaceuticals Source Type: news
Alphatec Spine to Host Investor Community Breakfast During the North American Spine Society Annual MeetingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CARLSBAD, Calif., Oct. 30, 2009 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, today announced it will host an Investor Community Breakfast for investors and analysts in conjunction with the North American Spine Society (NASS) Annual Meeting on Wednesday, November 11, 2009, from 7:30 a.m. to 9:00 a.m. Pacific Time at The InterContinental Hotel, San Francisco, California.
Source: Medical News (via PRIMEZONE) - October 30, 2009 Category: Pharmaceuticals Source Type: news
Pfizer Completes Consent SolicitationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Pfizer today announced that it has received the requisite consents to amend certain provisions of the indenture governing the following outstanding debt securities (the Securities) of Wyeth, its wholly owned subsidiary.
Source: Pharmaceutical Online News - October 30, 2009 Category: Pharmaceuticals Source Type: news
Pfizer's Board Of Directors Approves Shareholder Advisory Vote On Executive CompensationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Oct 29, 2009 - Pfizer Inc. (NYSE:
PFE) announced that its Board of Directors has approved giving
shareholders an advisory vote on executive compensation. The vote
will first occur at Pfizer's Annual Meeting of Shareholders...
Source: Drugs.com - Pharma News - October 30, 2009 Category: Pharmaceuticals Source Type: news
Momenta Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare ConferenceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CAMBRIDGE, Mass., Oct. 30, 2009 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Richard P. Shea, Chief Financial Officer, will deliver a corporate presentation at the Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3rd, at 9:40 am EST. The conference will be held at The Waldorf Astoria Hotel in New York City.
Source: Medical News (via PRIMEZONE) - October 30, 2009 Category: Pharmaceuticals Source Type: news
Transcept Pharmaceuticals Receives Complete Response Letter From FDA On Intermezzo(R) New Drug ApplicationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Transcept Pharmaceuticals (Nasdaq: TSPT) announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). The NDA, submitted by Transcept in September 2008, seeks approval to market Intermezzo® for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
Source: Pharma Industry News From Medical News Today - October 30, 2009 Category: Pharmaceuticals Tags: Sleep / Sleep Disorders / Insomnia Source Type: news
New Studies Demonstrate Benefits of Minimally Invasive Hysterectomy and Colectomy When Compared To Open Surgery(Oct 30, 2009)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Cincinnati, OH (October 26, 2009)– Ethicon Endo-Surgery today announced results from two newly published studies that demonstrate a minimally invasive approach in three common procedures resulted in a reduced rate of complications and lower overall cost of care, including a difference of more than $15,000 on average for minimally invasive colectomies, when compared to open surgery. One study compared two types of minimally invasive hysterectomy procedures to open abdominal hysterectomy1
Source: Johnson and Johnson - October 30, 2009 Category: Pharmaceuticals Source Type: organizations
Living Without BlockbustersEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Sanofi-Aventis' Christopher Viehbacher is slashing R&D and moving into emerging countries.
Source: Forbes.com Healthcare News - October 30, 2009 Category: Pharmaceuticals Source Type: news
FDA: Procter & Gamble Unlawfully Marketing Two Vicks Cold And Flu Medicines Containing Vitamin CEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The U.S. Food and Drug Administration today sent a warning letter to Procter & Gamble notifying the company that its Vicks DayQuil Plus Vitamin C and Vicks Nyquil Plus Vitamin C are illegally marketed combinations of drug ingredients and a dietary ingredient.
Source: Pharmaceutical Online News - October 30, 2009 Category: Pharmaceuticals Source Type: news
Lilly CEO Lechleiter Calls For Repair Of The 'Engine Of Biopharma InnovationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In a speech today to the City Club of San Diego, John C. Lechleiter, Ph.D., chairman and chief executive officer of Eli Lilly and Company (NYSE:
LLY), said that the engine of biopharmaceutical innovation is "broken." He offered a vision for biopharmaceutical companies to "reinvent innovation" to make the most of today's wealth of scientific knowledge to benefit patients and address unmet medical needs.
Source: Pharmaceutical Online News - October 30, 2009 Category: Pharmaceuticals Source Type: news
Drug Makers Face Tougher MeasuresEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The House health-care bill presents more problems for drug makers than legislation in the Senate, but it gives the medical-device industry better breaks.
Source: WSJ.com: Health - October 30, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Healing PowerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Ultrasound is said to heal chronic wounds that don't respond to other treatments.
Source: Forbes.com Healthcare News - October 30, 2009 Category: Pharmaceuticals Source Type: news
KantarHealth Expands CardioMonitor(TM) Into Japan and ChinaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
NEW YORK, Oct. 29, 2009 (GLOBE NEWSWIRE) -- KantarHealth is expanding its CardioMonitor service into Japan and China. A globally consistent cardiovascular and diabetes patient database, CardioMonitor will add 4,500 Japanese patients in December 2009 and 4,500 Chinese patients in February 2010. The new information will help pharmaceutical and biotech companies size opportunities, identify treatment dynamics, position products and sharpen forecasts in the growing Japanese and Chinese markets. Formed by uniting Consumer Health Sciences, MattsonJack, TNS Healthcare and Ziment, KantarHealth is the world's leading global healthc...
Source: Medical News (via PRIMEZONE) - October 30, 2009 Category: Pharmaceuticals Source Type: news
Novo Nordisk increased operating profit by 30% in the first nine months of 2009Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Sales increased by 15% in Danish kroner and by 11% in local currencies:
Sales of modern insulins increased by 28% (24% in local currencies).
Sales of NovoSeven® increased by 15% (11% in local currencies).
Sales of Norditropin® increased by 15% (9% in local currencies).
Sales in North America increased by 29% (17% in local currencies).
Sales in International Operations increased by 18% (16% in local currencies).
Source: World Pharma News - October 30, 2009 Category: Pharmaceuticals Source Type: news
AstraZeneca PLC Third Quarter & Nine Months Results 2009Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Revenue in the third quarter increased by 10 percent at CER, but was up 5 percent on an actual basis as a result of the negative impact of exchange rate movements. Revenue benefited from strong growth of the Toprol-XL franchise in the US as a result of the market withdrawal by two generic competitors and from revenues from US government orders for vaccine for Novel Influenza A (H1N1); adjusting for these factors, global revenue increased by 5 percent.
Source: World Pharma News - October 30, 2009 Category: Pharmaceuticals Source Type: news
Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy EndpointsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
THOUSAND OAKS, Calif., Oct. 30 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp?? Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes. The study, published online today in the New England Journal of Medicine and presented at the annual meeting of the American Society of Nephrology (ASN), failed to meet its primary objectives of demonstrating a reduction in all-cause mortality, cardiovas...
Source: Amgen News Service - October 30, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations
Drug Makers Face Tougher MeasuresEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The House health-care bill presents more problems for drug makers than legislation in the Senate, but it gives the medical-device industry better breaks.
Source: WSJ.com: Health - October 29, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
House Democrats Unveil Health BillEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
House health-care legislation includes a compromise version of a public insurance option and carries an overall cost of $894 billion over 10 years.
Source: WSJ.com: Health - October 29, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn's DiseaseEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
DUBLIN & SAN DIEGO--(BUSINESS WIRE)--Oct 27, 2009 - Elan
Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) today
announced data showing that treatment with TYSABRI®
(natalizumab) significantly reduced the rate of...
Source: Drugs.com - Clinical Trials - October 29, 2009 Category: Pharmaceuticals Source Type: clinical trials
Genta Incorporated Announces Conference Call to Review Top-Line Results of AGENDA Phase 3 Trial of Genasense in Patients with Advanced MelanomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
[webcast]
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Oct 28, 2009 - Genta
Incorporated (OTCBB: GETA) announced that the Company will host a
conference call and live audio webcast to review top-line results
of its Phase 3 trial of...
Source: Drugs.com - Clinical Trials - October 29, 2009 Category: Pharmaceuticals Source Type: clinical trials
Celldex Therapeutics Presents Positive Clinical Data from Phase 1 Studies of Antibody-Based Cancer Vaccine Candidate, CDX-1307Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
--Data presented at iSBTc meeting; Phase 2 initiation in
first quarter 2010--
NEEDHAM, Mass.--(BUSINESS WIRE)--Oct 29, 2009 - Celldex
Therapeutics, Inc. (NASDAQ: CLDX) today announced positive results
from Phase 1 studies of CDX-1307 in patients...
Source: Drugs.com - Clinical Trials - October 29, 2009 Category: Pharmaceuticals Source Type: clinical trials
TranS1 Inc. Reports Operating Results for the Third Quarter of 2009Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
WILMINGTON, N.C., Oct. 29, 2009 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products that implement its proprietary minimally invasive surgical approach to treat degenerative disc disease and instability affecting the lower lumbar region of the spine, today announced its financial results for the third quarter ended September 30, 2009.
Source: Medical News (via PRIMEZONE) - October 29, 2009 Category: Pharmaceuticals Source Type: news
Patient Portal Technologies Signs 5-Year Contract With Lifespan Health System's Miriam HospitalEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BALDWINSVILLE, N.Y., Oct. 29, 2009 (GLOBE NEWSWIRE) -- Patient Portal Technologies, Inc. (OTCBB:PPRG) announced today that its TB&A Television Services subsidiary has been awarded a multiyear, five hundred thousand dollar contract from Miriam Hospital, part of the five-hospital Lifespan health system, to provide leased television equipment, installation and maintenance services.
Source: Medical News (via PRIMEZONE) - October 29, 2009 Category: Pharmaceuticals Source Type: news
Aetna Earnings Rise 18%Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Aetna's profit rose 18% amid better returns from its investments, while costs related to the H1N1 flu hurt margins at its commercial plans.
Source: WSJ.com: Health - October 29, 2009 Category: Pharmaceuticals Tags: PAID Source Type: news
Orchid Cellmark to Present to the Harvard Investors GroupEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
PRINCETON, N.J., Oct. 29, 2009 (GLOBE NEWSWIRE) -- Orchid Cellmark Inc. (Nasdaq:ORCH), a leading international provider of identity DNA testing services, today announced that the company will be making a presentation to investors at a meeting organized by the Harvard Investors Group at Fraunces Tavern, located at 54 Pearl Street at Broad Street in New York City on November 4, 2009. Thomas A. Bologna, Orchid Cellmark's president and chief executive officer, will present at 5:15 p.m. EST.
Source: Medical News (via PRIMEZONE) - October 29, 2009 Category: Pharmaceuticals Source Type: news
AZ to settle US marketing caseEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
AstraZeneca is poised to pay more than $500m to settle allegations in the US of marketing abuses of its second-most important drug
Source: FT.com - Drugs and Healthcare - October 29, 2009 Category: Pharmaceuticals Source Type: news
H1N1 Cases Vastly UnderreportedEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The number of confirmed cases of H1N1 flu from April to July represents 2% of the actual people who were infected with the virus, according to a new U.S. report.
Source: WSJ.com: Health - October 29, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
